Lantheus Holdings, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Mary Anne Heino
- Full Time Employees
- 1,193
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 201 Burlington Road Bedford MA United States of America 01730
- IPO Date
- Jun 25, 2015
- CIK
- 0001521036
- Website
- lantheus.com
- Similar Companies
- Business
- Lantheus Holdings, Inc. is a global biopharmaceutical company specializing in the development, manufacturing, and commercialization of diagnostic imaging agents and radiopharmaceuticals. The company’s core product portfolio includes radiopharmaceuticals for positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging, contrast agents for echocardiography such as DEFINITY® Vial, and generator systems like TechneLite® for technetium-99m production used in nuclear medicine. Lantheus also offers contract development and manufacturing organization (CDMO) services for diagnostic agents and specialty pharmaceuticals, supporting clinical development and commercial manufacturing. Its products primarily serve the oncology, cardiology, and neurology markets, aiding in the diagnosis and management of serious diseases. The company operates globally with headquarters in North Billerica, Massachusetts, and was founded in 1956. In the past two years, Lantheus has undergone significant strategic expansion through acquisitions and product pipeline growth. Notably, it acquired Evergreen Theragnostics in 2025 for $250 million upfront with additional milestone payments, enhancing its radiopharmaceutical capabilities by incorporating scalable manufacturing infrastructure and expanding its oncology diagnostic pipeline with products like OCTEVY™, a PET diagnostic for neuroendocrine tumors. Additionally, Lantheus completed the acquisition of Life Molecular Imaging in mid-2025 for up to $750 million, adding the FDA-approved F-18 PET agent Neuraceq used to detect beta-amyloid plaques in Alzheimer’s disease, a significant complement to its diagnostic portfolio. These acquisitions reinforce Lantheus' strategy to become a fully integrated radiopharmaceutical company encompassing drug development, manufacturing, and commercialization. The company has also announced plans to divest its SPECT business to focus on higher-growth radiopharmaceuticals. Lantheus continues to innovate in molecular imaging with a robust pipeline including new radiotracers targeting cancers and neurological conditions. It supports healthcare providers with clinical education and comprehensive solutions across the diagnostic imaging value chain. In 2025, the company implemented a $400 million stock repurchase program and adjusted its financial guidance reflecting short-term pressures but emphasizing long-term growth through its growing commercial portfolio and clinical assets. Leadership changes during 2025 include executive role shifts to strengthen commercial and operational capabilities. Lantheus is positioning itself as a leader in radiopharmaceutical innovation serving oncology, cardiology, and neurology markets globally.
Company News
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs
Are LNTH, ITGR, CZR Obtaining Fair Deals for their Shareholders?
Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc. - LNTH
LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders
LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders
US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment
Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer's Disease
Are DSGR, LNTH, ATKR Obtaining Fair Deals for their Shareholders?
Are DSGR, LNTH, ATKR Obtaining Fair Deals for their Shareholders?
Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc. - LNTH
Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc. - LNTH
Lantheus Reports Second Quarter 2026 Financial Results
First Trust Advisors LP Purchases 44,713 Shares of Lantheus Holdings, Inc. $LNTH
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lantheus Holdings, Inc. (NASDAQ: LNTH)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lantheus Holdings, Inc. (NASDAQ: LNTH)
Are SUPN, ITGR, ATKR, LNTH Obtaining Fair Deals for their Shareholders?
Are SUPN, ITGR, ATKR, LNTH Obtaining Fair Deals for their Shareholders?
Shareholder Alert: Ademi LLP investigates whether Lantheus Holdings, Inc. is obtaining a Fair Price for Public Shareholders
Shareholder Alert: Ademi LLP investigates whether Lantheus Holdings, Inc. is obtaining a Fair Price for Public Shareholders